"This joint award signifies the growing importance of the relationship between the United States and China in cancer research."
- Wei Zhang, Ph.D.
Bethesda, MD (PRWEB) June 17, 2011
The National Foundation for Cancer Research and the U.S. Chinese Anti-Cancer Association have jointly awarded three young Chinese cancer researchers the 2011 Scholar Excellence Award for outstanding achievements in cancer research while they were in the United States and for continuing contributions to fighting cancer after they returned to China.
The Chinese Journal of Cancer featured the Awards in its June 2011 issue by inviting each of three 2011 recipient and two 2010 recipients to write a summary of the research they conducted while pursuing academic degrees at leading universities in the United States.
“It is a privilege to honor these five outstanding scientists for their dedicated work in the field of cancer research,” said Franklin C. Salisbury, Jr., President of NFCR. “They are the next generation of research leaders. Each of the breakthroughs they will achieve will take us a step closer to finding a cure for cancer.”
“Working with the National Foundation for Cancer Research, we are bringing these young, bright minds new and well-deserved recognition,” said Wei Zhang, Ph.D., Professor and Director of the Cancer Genomics Core Laboratory at MD Anderson Cancer Center and President of the Chinese Anti-Cancer Association. “This joint award signifies the growing importance of the relationship between the United States and China in cancer research.”
The recipients of the Award are:
- Dr. Yong Gao, Affiliated East Hospital, Tongji University, Shanghai
- Dr. Ji-Long Yang, Tianjin Medical University Cancer Hospital and Institute, Tianjin
- Dr. Pei-Rong Ding, Sun Yat-sen University Cancer Center, Guanzhou
- Dr. Min Huang, Shanghai Institute of MateriaMedica, Chinese Academy of Sciences, Shanghai
- Dr. Ying-Mei Wang, Tianjin Medical University General Hospital, Tianjin
The common goal of NFCR and USCACA is to expedite new cancer drug development by stimulating the translation of laboratory discoveries into cancer treatments, fostering collaborations in clinical cancer drug development, and sharing best practices and knowledge between China and the United States. This award, established in November 2010, is part of the USCACA-NFCR Scholar Exchange and Fellowship Program. The Program provides a unique opportunity for young Chinese scholars who have an interest in advancing their research skills and knowledge to establish long-term collaborations with leading scientists in the United States who can support their continued work and future success in China.
About the National Foundation for Cancer Research
The National Foundation for Cancer Research (NFCR) is a leading cancer research charity dedicated to funding innovative cancer research and public education relating to cancer prevention, earlier diagnosis, better treatments and, ultimately, a cure for cancer. NFCR promotes and facilitates collaboration among scientists to accelerate the pace of discovery from bench to bedside.
Since 1973, NFCR has provided over $288 million in support of discovery-oriented cancer research focused on understanding how and why cells become cancerous, and on public education relating to cancer prevention, detection, and treatment. NFCR scientists are discovering cancer’s molecular mysteries and translating these discoveries into therapies that hold the hope for curing cancer. NFCR is about Research for a Cure—cures for all types of cancer. For more information, please visit http://www.NFCR.org.
About the U.S.-Chinese Anti-Cancer Association
USCACA is a not-for-profit professional organization founded in 2009. With members from academia, industry and government, USCACA facilitates collaborations among cancer researchers and physicians in the United States and China. Its current focus is on expediting novel cancer drug development by fostering clinical trial networks, sharing best practices and knowledge of clinical trials, and providing education and training opportunities. USCACA collaborates with the Chinese Anti-Cancer Association (CACA), the Chinese Society for Clinical Oncology, and other professional associations, with a mandate is to improve cancer treatment through research, education, and collaboration. For more information, visit http://www.uscaca.org.
# # #